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Abstract 
Objective: 1) Examine population-based overall and malformation-specific trends in the prenatal 
diagnosis, pregnancy termination and perinatal mortality for congenital heart disease(CHD) 
during a period of rapid progress in prenatal diagnosis and medical management of CHD; 2) 
Explore the impact of prenatal diagnosis on early neonatal mortality for specific(isolated) cardiac 
malformations. 
Methods: 1982 cases of CHD, which were not associated with a known chromosomal anomaly, 
were obtained from the Paris Registry of Congenital Malformations. Main outcome measures 
were trends in the proportions diagnosed and terminated prior to birth, stillbirth and early(<1 day, 
one-week) neonatal mortality for: i) all cases, ii) all cases excluding isolated ventricular septal 
defects, and iii) malformation-specific trends for transposition of great arteries(TGA), 
hypoplastic left heart syndrome(HLHS), coarctation of aorta, and tetralogy of Fallot. Analyses 
included cusum and binomial regression models for analysis of the trends during 1983-2000.  
Results: Prenatal diagnosis rates for CHD increased from 23.0% (95%CI, 19.0-27.4) in 1983-
1988 to 47.3% (95%CI, 43.8–50.8) in 1995-2000. Termination rates increased between 1983-
1989 (9.9%, 95%CI, 7.2-13.2) and 1989-1994 (14.7%, 95%CI, 12.3-17.4) but appeared to remain 
stable thereafter. Other than for HLHS, pregnancy termination was exceptional for the other three  
specific malformations examined. Early neonatal mortality decreased to less than a third in the 
period 1995-2000 as compared with 1983-1989 (RR, first week mortality, 0.31, 95%CI, 0.18-
0.53). First week mortality was significantly lower for cases of TGA diagnosed prior to birth 
(Risk Difference, 15.4%, 95% CI, 4.0-26.7). 
Conclusions: Progress in clinical management, together with policies for increased access to 
prenatal diagnosis has resulted in both a substantial increase in the prenatal diagnosis, and 
considerable reductions in early neonatal mortality of CHD in the Parisian population. 
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Introduction 
Congenital heart disease (CHD) is the most common congenital anomaly
1,2
 and a major 
cause of mortality and morbidity in the perinatal period
3
. The reported prevalence of CHD is 
subject to a great deal of variation across different populations and registries, presumably for the 
most part due to differences in the inclusion of milder anomalies
2,4
. On the other hand, the 
reported prevalence of severe CHD appears to be fairly constant across different populations and 
is approximately 3.0 per 1,000 live births. Differences exist however in the rates of prenatal 
diagnosis and termination of CHD across populations
5,6
 and over time
4,7,8
, which can have an 
impact on the livebirth prevalence of the more severe cases of CHD
9




France pursues an active policy of antenatal surveillance, particularly for prenatal 
diagnosis of congenital anomalies
11,12
. Prenatal diagnosis of structural CHD with transabdominal 
ultrasonography began in the early 1980s and became widespread in the late 1980s
13
. Detection 
rates for structural heart defects have been shown to be higher in France than other European 
countries
5,6,14
 or the United States
7
. However, the impact of prenatal diagnosis on the outcomes of 
newborns with structural heart disease has been difficult to evaluate
15
, mostly due to problems 
related to selection bias as cases that are more likely to be diagnosed prenatally tend to be the 
more severe cases. Hence, not surprisingly previous studies have often found overall poorer 
outcomes in cases of CHD that are diagnosed prenatally
7,16-18
. The impact of prenatal diagnosis 
has been shown to vary considerably across different malformations with improved outcomes 
reported for prenatally diagnosed cases of coarctation of aorta and transposition of great 
arteries
17,19-23
. Nevertheless, even findings from the studies that have assessed the same set of 
anomalies have not been consistent
19-22




evaluated the impact of prenatal diagnosis on neonatal outcomes and none have examined the 
entire period that spans the introduction of screening in the 1980s until the most recent period.  
In this study, we examine overall and malformation-specific trends in the prenatal 
diagnosis, pregnancy termination and perinatal mortality due to congenital heart disease using 
population-based data from the Paris Registry of Congenital Malformations for the years 1983 to 
2000. We also assess trends in the timing of prenatal diagnosis and pregnancy termination. In 
addition, we explore the impact of prenatal diagnosis on early neonatal mortality for hypoplastic 
left heart syndrome and transposition of great arteries for which previous hospital-based studies 




Materials and Methods  
Data  
2440 cases of congenital heart disease were obtained from the Paris Registry of 
Congenital Malformations for the years 1983 – 2000. The base study population corresponded to 
births and terminations of pregnancy to women who were residents of Paris and gave birth or had 
a termination of pregnancy in a Parisian maternity during the period 1983-2000 (Total number of 
births = 452,867). Data for the Registry are collected from multiple sources of information, 
including maternity units, neonatology services, cytogenetic and pathology services, in order to 
allow high case ascertainment for malformations and chromosomal abnormalities. Registration is 
essentially complete for cases identified during the initial hospitalization for delivery or for those 
identified in the post-mortem examination. The registration, including mortality outcomes are not 
complete however for late diagnoses or for mortality outcomes beyond the early (first week) 
neonatal period. 
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The diagnosis for each case was either based on an evaluation by a pediatric cardiologist 
as documented in the medical chart or on post-mortem examination. Cases were classified 
following the International Classification of Disease 9.0 and included i) bulbus cordis anomalies 
and anomalies of cardiac septal closure (ICD9 code 745),  ii) other congenital anomalies of the 
heart (ICD9 code 746) and iii) other congenital anomalies of circulatory systems (ICD9 code 
747).  Cardiac anomalies associated with a known chromosomal anomaly comprised 18.1% (N = 
458) of cases. These cases were excluded from further analyses. Hence, the study population 
comprised 1982 cases of congenital heart disease. In addition, 13 cases (0.7 %) had missing 
information on prenatal diagnosis and were excluded from the analyses of trends in prenatal 
diagnosis.  
Main outcome measures for the study were trends in the proportion diagnosed and/or 
terminated prior to birth, perinatal (stillbirth plus early neonatal mortality) and early (<24 hours, 
one-week) neonatal mortality of cases not associated with a chromosomal anomaly. Trends were 
examined for: i) all cases, ii) all cases excluding isolated ventricular septal defects, and iii) 
malformation-specific trends for isolated cases of transposition of great arteries, hypoplastic left 
heart syndrome, coarctation of aorta, and tetralogy of Fallot. We also assessed timing of prenatal 
diagnosis and pregnancy termination by examining trends in the median gestational age at 
diagnosis and at termination. 
Analyses that excluded isolated ventricular septal defects, and the malformation-specific 
analyses were undertaken in order to: a) partially control for the potential selection bias due to 
increasing diagnosis of less severe cases over time, and b) examine heterogeneities in prenatal 
diagnosis and outcomes for four major anomalies.  In order to assess the impact of associated 
malformations on study outcomes, we examined the prenatal diagnosis, pregnancy termination 
and perinatal mortality of the isolated cases of CHD for the most recent period (1995-2000). For 
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this analysis, isolated cases of CHD were defined as those that were not associated with another 
major, non-cardiac malformation. During this period, approximately 17% of cases (among those 
without a known chromosomal anomaly) were associated with at least one other major non-
cardiac malformation.  
 
Statistical Analysis 
We report proportions with 95% binomial exact confidence intervals. We used cusums for 
nonparametric analysis of time trends in binary variables
25
. This technique allows detection of 
significant monotonic (always increasing / decreasing) and nonmonotonic (e.g., quadratic) trends. 
Inverted U-shaped curves of cusums over time suggest a monotonically increasing trend in 
proportions over time, whereas U-shaped curves suggest a monotonically decreasing trend. We 
also used binomial regression models
26
 for analysis of maternal age-adjusted trends in the study 
outcomes. Maternal age was considered a potential confounding variable in the analyses of trends 
since: i) there has been a consistent trend towards delayed childbearing in the Parisian population,  
and ii) the prenatal surveillance of older women might be different from their younger 
counterparts; as older women are at higher risk for adverse pregnancy outcomes including 
congenital anomalies. The Kruskal-Wallis test was done to test the statistical significance of 
trends in the timing of prenatal diagnosis and pregnancy termination. 
Binomial regression was also used for analysis of time period-adjusted effect of prenatal 
diagnosis on neonatal mortality of infants born with transposition of great arteries. This was done 
to control for the potentially confounding effect of time. Such confounding could arise since: i)  
the rate of prenatal diagnosis of transposition of great arteries has increased over time; ii) the 
spectrum of severity of cases diagnosed might have changed over time; and iii) the clinical 
management (medical as well as surgical) of infants born with transposition of great arteries has 
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in all likelihood improved over time (in ways that might not be directly or indirectly related to 




Prenatal diagnosis  
The proportion of CHD cases diagnosed prenatally increased from 23.0 % (95% CI, 19.0 
– 27.4) in 1983 – 1988 to 47.3% (95% CI, 43.8 – 50.8) in 1995 – 2000 (Table 1). Cusum analysis 
suggested a monotonically increasing time trend in the proportion of cases diagnosed prior to 
birth (Figure 1, p < 0.001). This was true both for all cases and for all cases excluding isolated 
ventricular septal defects (Table 1). Compared with the period 1983-1988, there was an increase 
of 34% in maternal age-adjusted probability of prenatal diagnosis for CHD in 1989 – 1994 (Age-
adjusted Risk Ratio (RR) 1.34, 95% CI, 1.09 – 1.65), and a two-fold increase (Age-adjusted RR 
1.99, 95% CI, 1.64 – 2.41) in the prenatal diagnosis of CHD in 1995 – 2000 (Table 2). Analysis 
of prenatal diagnosis rates for isolated cases only during the most recent period (1995 – 2000) 
suggested essentially the same prenatal diagnosis rates; the proportion of isolated cases with a 
prenatal diagnosis was 45.4% (95% CI, 41.4-49.5) as compared with 47.3% (95% CI, 43.8-50.8) 
for all cases.   
Trends in prenatal diagnosis differed substantially across the four specific malformations 
examined (Table 3). However, for all four malformations there were significant increases in the 
proportion of cases diagnosed prenatally over time. By the most recent period, approximately ¾ 
of the cases of the transposition of great arteries (72.5%, 95% CI, 56.1 – 85.4) , 90% of the cases 
of hypoplastic left heart syndrome (88.9%, 95% CI, 70.8 – 97.6), 40% of the cases of  coarctation 
of aorta (42.4%, 95% CI, 25.5 – 60.8) and 70% of cases of tetralogy of Fallot (69.7%, 95% CI, 
51.3 – 84.4) were diagnosed prenatally. 
Gestational age at prenatal diagnosis decreased significantly over time (Kruskal-Wallis 
test, p = 0.001). The median gestational age at diagnosis was 27 weeks during the period 1983 – 
1988, 25 weeks in 1989 – 1994 and 23 weeks in 1995 – 2000. Gestational age at diagnosis also 
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decreased significantly for cases that were terminated; median gestational age at diagnosis was 24 
weeks in 1983 – 1988, 23 weeks in 1989 – 1995 and 22 weeks in 1995 – 2000 (p = 0.0005). In 
particular, timing of prenatal diagnosis decreased significantly for cases of hypoplastic left heart 
syndrome; 24 weeks, 23 weeks, and 21 weeks of gestation for the three periods, respectively (p = 
0.04).  
 
Pregnancy termination  
 The proportion of cases of CHD that were terminated prior to birth increased between 
1983 – 1988 and 1989 – 1994 but appeared to remain stable thereafter (Tables 1 and 2). Overall, 
approximately 15% of the cases were terminated in 1995 – 2000 (15.4%, 95% CI, 13.0 – 18.1). 
The pregnancy termination rates for the isolated cases appeared to be somewhat lower (12.2%, 
95% CI, 9.7 – 15.1) during this same period. This difference did not reach statistical significance 
however.  
During the most recent period, almost half of the cases terminated (45.4%, 95% CI, 33.5 – 
57.3) were accounted for by “complex” CHD involving at least two distinct anomalies (ICD 9 
codes) . During this same period, the most frequent cases of CHD terminated involved 
hypoplastic left heart syndrome, univentricular heart, and to a lesser extent, pulmonary valve 
abnormalities (e.g., pulmonary atresia), atrioventricular septal defect, and congenital aortic valve 
stenosis.  
Other than for hypoplastic left heart syndrome, termination of pregnancy was exceptional 
in the case of the other three specific malformations examined (Table 3). In contrast, more than 
60% of the cases of hypoplastic left heart syndrome were terminated in the more recent periods, 
72.4% (95% CI, 52.8 – 87.3) in 1989 – 1994, and 63.0% (95% CI, 42.4 – 80.6) in 1995 – 2000.      
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Median gestational age at termination did not change significantly over time; median age 
at termination was 25 weeks in 1983 – 1988 and 1989 – 1994, and 24 weeks in 1995 – 2000 ( p = 
0.18). Timing of pregnancy termination did not appreciably change for the cases of hypoplastic 
left heart syndrome either. 
 
Perinatal mortality 
 Perinatal mortality decreased substantially for congenital heart disease over time to almost 
a third in 1995 – 2000 (Maternal age-adjusted RR, 0.38, 95% CI, 0.27 – 0.57) as compared with 
1983 – 1988 (Table 2). Cusum analysis suggested a monotonically decreasing trend over time 
(Figure 2, p < 0.001). Stillbirth, first day and first week neonatal mortality all decreased 
substantially over time; however, the trends appeared to be greater for neonatal mortality than for 
stillbirth (Table 1). Stillbirth rate decreased by about one half (Maternal age-adjusted RR, 0.49, 
95% CI, 0.27 – 0.87), whereas early neonatal mortality of newborns with congenital heart disease 
decreased to less than a third in the period 1995-2000 as compared with 1983-1989 (Table 2); 
first day mortality, maternal age-adjusted RR 0.30, 95%CI, 0.11 – 0.82, and first week mortality, 
adjusted RR 0.31, 95%CI, 0.18 - 0.53).   
 Analysis of mortality outcomes for isolated cases showed comparable perinatal and 
neonatal mortality rates. For example, the perinatal mortality rates for all cases was 6.4% (95% 
CI, 4.7 – 8.5) during 1995 – 2000 as compared with 5.1% (95% CI, 3.4 – 7.4) for isolated cases. 
Similarly, the first week mortality was 3.3% (95% CI, 2.1 – 5.0) for all cases during 1995 – 2000 
as compared with 3.7% (95% CI, 2.2 – 5.7) for the isolated cases. In general, as isolated cases 
accounted for the overwhelming majority (> 80%) of cases, their outcomes determined to a large 
extent the overall outcomes for the cases of CHD. 
 11 
 There was a substantial decrease in perinatal mortality due to transposition of great 
arteries and hypoplastic left heart syndrome over time (Table 3);  however, differences did not 
reach statistical significance for the latter ( p = 0.10). For transposition of great arteries, first 
week neonatal mortality decreased from approximately 19% in 1983 – 1988 (18.8%, 95% CI, 4.0 
– 45.6) to about 3% (2.6%, 95% CI, 0.1 – 13.5) in 1995 – 2000 ( p = 0.04). For coarctation of 
aorta and tetralogy of Fallot, the number of isolated cases was not sufficient to assess trends over 
time.  
Finally, first week mortality was significantly lower for cases of transposition of great 
arteries diagnosed prior to birth (Fischer’s Exact test, p = 0.01); the mortality rate was 15.4% for 
cases diagnosed after birth (N = 39) as compared with 0% for cases diagnosed prior to birth (N = 
39); Risk Difference, 15.4% (95% CI, 4.0 – 26.7). This difference decreased slightly but 
remained statistically significant after adjustment for time period (Time period-adjusted Risk 
Difference, 12.8%, 95% CI, 0.002 – 25.3%). On the other hand, we did not find any evidence for 
a significant impact of prenatal diagnosis on early neonatal mortality for hypoplastic left heart 
syndrome; the first week neonatal mortality rate was 69.2% for prenatally diagnosed cases (N = 
13), and 73.9% for cases diagnosed postnatally (N = 23).  
 12 
Discussion 
 In summary, we found substantial increases in prenatal diagnosis of congenital heart 
disease in the Parisian population over the study period. Currently, more than 50% of the cases of 
CHD that are not associated with a known chromosomal anomaly are likely to be diagnosed 
prenatally. Prenatal diagnosis occurred at a significantly earlier time over the study period, in 
particular for cases that were terminated. Trends varied substantially across different 
malformations examined. Our results suggest that almost 90% of the cases of hypoplastic left 
heart syndrome are diagnosed prenatally and 60% are terminated prior to birth. Overall, 
termination rates increased between 1983 - 1988 and 1989 - 1994 but appeared to remain stable 
thereafter. Timing of pregnancy termination did not appreciably change during the study period.  
 By the end of 1990s, perinatal mortality due to CHD decreased to about one-third its rate 
in the 1980s. This was particularly the case for the transposition of great arteries for which early 
neonatal mortality decreased to about one-sixth. Prenatal diagnosis of transposition of great 
arteries was associated with a substantially lower first week neonatal mortality. This effect of 
prenatal diagnosis remained significant after adjustment for time period. On the other hand, we 
did not find a significant effect for prenatal diagnosis on early neonatal mortality of hypoplastic 
left heart syndrome.  
The interpretation of our results is subject to several caveats and limitations. One potential 
source of bias that might lead to overestimation of prenatal diagnosis rates relates to the 
possibility of incomplete case ascertainment. This might be particularly the case for infants born 
with CHD who had a late diagnosis or those that were undiagnosed. Some of the latter may  
comprise less severe cases that remain asymptomatic during the early neonatal period. It is 
important in general to distinguish sources of bias that concern baseline rates, e.g., incomplete 
case ascertainment because of limited registration that only includes early neonatal period, from 
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sources of bias that might be related to trends over time. We are not aware of any reason to 
expect that case ascertainment in the postnatal period decreased over time. Hence, the time trends 
we observed are likely to reflect true increases in prenatal diagnosis of CHD.   
Another important potential source of bias relates to the observed increase in number of 
CHD cases over time. There are four potential explanations for such trend: i) increased prenatal 
and early postnatal diagnosis of cases over time, and in particular increased diagnosis of less 
severe cases (e.g., isolated ventricular septal defects) as a result of progress in cardiac 
echography; ii) increased post-mortem diagnosis of anomalies as the Registry data suggest that 
post-mortem examinations for congenital anomalies have increased over time
27
; iii) referral bias, 
which we attempted to minimize by including only women who resided in Paris and gave birth at 
a Parisian maternity unites; and iv) increase in maternal age-related chromosomal anomalies 
(most importantly Trisomy 21) that are associated with congenital heart disease. To minimize the 
latter, we excluded all congenital heart defects that were associated with known chromosomal 
anomalies.  
Perhaps the most important source of potential bias that could result in underestimation of 
mortality rates due to CHD over time relates to increased diagnosis and hence inclusion of less 
severe cases. Such selection bias could potentially explain all or part of the observed trends for 
lower perinatal mortality over time. We conducted the analyses that excluded isolated ventricular 
septal defects in order to partially control for such selection. Indeed, both the baseline outcomes 
and time trends did differ for the subset of CHD that excluded isolated ventricular septal defects. 
However, differences in trends for mortality with or without inclusion of isolated ventricular 
septal defects were most notable between 1983 – 1988 and 1989 – 1994. By the most recent 
period (1995 – 2000), trends in perinatal mortality were essentially the same for all CHD 
combined and the subset of CHD that excluded isolated ventricular septal defects.  
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The absolute number of deaths due to CHD also decreased over time, further suggesting 
that increases in the registered cases of CHD (i.e., the denominators for mortality rates) do not 
entirely explain the observed decreases in mortality over time. Moreover, the malformation-
specific trends are presumably less subject to selection bias due to inclusion of less severe cases 
over time. Therefore, for the four specific malformations examined, the severity of cases might 
not have changed substantially over time. In any case, our results regarding trends in mortality 
rates due to CHD cannot be considered as definitive as data limitations preclude a complete 
control for selection bias.  
The observed decreases in perinatal mortality might have been in part related to the 
increases in pregnancy termination for severe cases of CHD. Indeed, termination rates 
significantly increased between 1983 – 1988 and 1989 – 1994. Nevertheless, while termination 
rates remained essentially stable between 1989 – 1994 and 1995 – 2000, perinatal mortality, and 
in particular early neonatal mortality continued to decrease, both overall and for the four specific 
malformations examined.  
Our analyses of trends in perinatal mortality were limited to the early neonatal period 
(first week). While the Paris Registry includes data on mortality up to one year of age, the data 
beyond the first week is not collected systematically. In our analyses of available data for infant 
(i.e., up to one year of age) mortality, we found similar trends as those we report here for first 
week mortality (data available upon request). However, a full evaluation of the question of late 
neonatal and postneonatal mortality of infants born with CHD requires population-based data 
with complete assessment of mortality up to one year of age. In addition, we had limited power in 
assessing trends in perinatal mortality due to specific malformations, in particular for coarctation 
of aorta and tetralogy of Fallot.  
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Our findings on the survival advantage of prenatally diagnosed cases of transposition of 
great arteries are consistent with those reported based on a large hospital-series by Bonnet and 
colleagues
19
 from a major pediatric cardiology center in Paris. Our results differ however from 
those of Kumar et al
20
. Potential explanations for these differences include: i) variations in case 
ascertainment, in particular, inclusion of deaths due to CHD not diagnosed during life, which was 
done in the study by Bonnet et al and in our study; ii) differences in case-mix not accounted for 
by our control for time period; and iii) clinical management, or other factors related to 
organization of services in the different populations studied. 
In conclusion, progress in clinical management, together with policies for increased 
access to prenatal diagnosis has resulted in a substantial increase in the prenatal diagnosis, and a 
considerable reduction in perinatal mortality of infant with CHD in the Parisian population. This 
does not imply however that prenatal diagnosis generally confers a survival advantage to infants 
born with CHD. Findings from our study and the available evidence in the literature suggest that 
prenatal diagnosis might have improved the outcomes for certain anomalies. Nevertheless, much 
of the improvement in outcomes for CHD probably came about as a result of progress in 
postnatal medical and surgical care of newborns with CHD. At the same time, increased prenatal 
diagnosis of CHD has provided a greater opportunity for consultation between healthcare 
professionals and parents, and thereby the possibility for more informed decision-making for 
parents and their caregivers.  
Our findings need to be corroborated and expanded upon using population-based data 
from a reasonably large cohort of newborns with CHD with sufficient follow-up and detailed 
assessment of diagnoses and outcomes. In addition, with the improvements in the survival of 
infants with CHD, it becomes increasingly important to evaluate the role of prognostic factors 
including that of prenatal diagnosis in determining the mortality, morbidity and in particular 
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neurodevelopmental outcomes of infants with congenital heart disease
28
. Heterogeneities in 
outcomes across different cardiac anomalies
15,17,19-21,23
 and for given anomalies at different 
centers
19,20,29,30
, disparities in outcomes across socioeconomic groups
31,32
, and alternative 
strategies for antenatal screening of CHD
33-35
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Table 1 - P renatal diagnosis, pregnancy term ination, perinatal and early neonatal m ortality for congenital heart disease

 - Paris R egistry of 
C ongenital M alform ations, 1983-2000
Prenatal D iagnosis N
#
%  95 %  C I* N %  95 %  C I* N %  95 %  C I* p

A ll 409 23.0 19.0 - 27.4 755 31.7 28.3 - 35.1 805 47.3 43.8 - 50.8 < 0.001
A ll except V SD ** 297 31.0 25.8 - 36.6 480 47.5 43.0 - 52.1 567 61.4 57.2 - 65.4 < 0.001
Pregnancy Term ination
A ll 415 9.9 7.2 - 13.2 755 14.7 12.3 - 17.4 812 15.4 13.0 - 18.1 0.037
A ll except V SD ** 303 13.5 9.9 - 17.9 480 23.1 19.4 - 27.2 574 21.8 18.5 - 25.4 0.010
Stillbirth
A ll 374 7.0 4.6 - 10.0 644 4.0 2.7 - 5 .9 687 3.2 2.0 - 4 .8 0.028
A ll except V SD ** 262 9.2 6.0 - 13.3 369 6.8 4.4 - 9 .8 449 4.5 2.7 - 6 .8 0.021
First D ay M ortality
A ll 348 2.9 1.4 - 5 .2 618 1.1 0.5 - 2 .3 665 1.1 0.4 - 2 .2 0.075
A ll except V SD ** 238 4.2 2.0 - 7 .6 344 2.0 0.8 - 4 .1 429 1.6 0.7 - 3 .3 0.132
First W eek M ortality
A ll 348 10.1 7.1 - 13.7 618 4.9 3.3 - 6 .9 665 3.3 2.1 - 5 .0 < 0.001
A ll except V SD ** 238 14.7 10.5 - 19.9 344 8.7 6.0 - 12.2 429 4.9 3.1 - 7 .4 < 0.001
Perinatal M ortality
A ll 374 16.3 12.7 - 20.5 644 8.7 6.6 - 11.1 687 6.4 4.7 - 8 .5 < 0.001
A ll except V SD ** 262 22.5 17.6 - 28.1 369 14.9 11.4 - 19.0 449 9.1 6.6 - 12.2 < 0.001
* 95%  binom ial exact confidence interval

C ases w ith chrom osom al anom alies w ere excluded.
# 
For prenatal diagnosis and pregnancy term inations, the denom inators (N ) w ere the total num ber of cases (stillbirths +  live births +  term inations of 
pregnancy) w ith congenital heart disease. For stillbirth  and perinatal m ortality, the denom inator w as stillbirths +  live births, and for neonatal 
m ortality, the denom inator w as live births.
**Isolated ventricular septal defects

test of significance for cusum  linear annual trend
1983 - 1988 1989 - 1994 1995 - 2000
Table 2 - M aternal age-adjusted trends in  prenatal diagnosis, pregnancy term ination, perinatal and early neonatal m ortality for congenital heart
disease

Prenatal D iagnosis A djusted R R * 95%  C I A djusted R R * 95%  C I A djusted R R * 95%  C I
A ll 1.0 R eference 1.34 1.09 - 1 .65 1.99 1.64 - 2 .41
A ll except V SD ** 1.0 R eference 1.49 1.23 - 1 .81 1.93 1.61 - 2 .31
Pregnancy Term ination
A ll 1.0 R eference 1.47 1.05 - 2 .06 1.56 1.12 - 2 .18
A ll except V SD ** 1.0 R eference 1.70 1.22 - 2 .36 1.63 1.17 - 2 .25
Stillbirth
A ll 1.0 R eference 0.57 0.34 - 0 .97 0.46 0.26 - 0 .80
A ll except V SD ** 1.0 R eference 0.73 0.43 - 1 .26 0.49 0.27 - 0 .87
First D ay M ortality
A ll 1.0 R eference 0.37 0.14 - 0 .95 0.28 0.10 - 0 .77
A ll except V SD ** 1.0 R eference 0.44 0.17 - 1 .14 0.30 0.11 - 0 .82
First W eek M ortality
A ll 1.0 R eference 0.47 0.29 - 0 .76 0.31 0.18 - 0 .53
A ll except V SD ** 1.0 R eference 0.58 0.37 - 0 .93 0.31 0.18 - 0 .53
Perinatal M ortality
A ll 1.0 R eference 0.53 0.37 - 0 .74 0.38 0.26 - 0 .55
A ll except V SD ** 1.0 R eference 0.66 0.47 - 0 .92 0.39 0.27 - 0 .57
* M aternal age-adjusted risk ratio

C ases w ith chrom osom al anom alies w ere excluded.
**Isolated ventricular septal defects
1995 - 20001983 - 1988 1989 - 1994
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Figure 1 – Cusum plot for analysis of time trends in prenatal diagnosis of congenital heart disease*, Paris Registry of Congenital 
Malformations, 1983 – 2000. The inverted U-shaped curve suggests a monotonically increasing trend in proportion of CHD cases 















* Cases associated with chromosomal anomalies were excluded. 
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Table 3 - P renatal diagnosis, pregnancy term ination, perinatal and early neonatal m ortality for selected (isolated) congenital heart anom alies - 
 Paris R egistry of C ongenital M alform ations, 1983-2000
i) T ransposition of G reat A rteries
N %  95 %  C I* N %  95 %  C I* N %  95 %  C I* p

Prenatal D iagnosis 16 12.5 1.6 - 38.3 27 48.1 28.7 - 68.1 40 72.5 56.1 - 85.4 0.001
Pregnancy Term ination 17 0 0 - 19.5 27 7.4 0.9 - 24.3 40 0 0 - 8 .8 0.62
First W eek M ortality 16 18.8 4.0 - 45.6 24 8.3 1.0 - 27.0 39 2.6 0.1 - 13.5 0.04
Perinatal M ortality 17 23.5 6.8 - 49.9 25 12.0 2.5 - 31.2 40 5.0 0.6 - 16.9 0.02
ii) H ypoplastic Left H eart Syndrom e
N %  95 %  C I* N %  95 %  C I* N %  95 %  C I* p

Prenatal D iagnosis 22 31.8 13.9 - 54.9 29 82.8 64.2 - 94.2 27 88.9 70.8 - 97.6 < 0.001
Pregnancy Term ination 22 13.6 2.9 - 34.9 29 72.4 52.8 - 87.3 27 63.0 42.4 - 80.6 < 0.001
First W eek M ortality 18 83.3 58.6 - 96.4 8 75.0 34.9 - 96.8 10 50.0 18.7 - 81.3 0.12
Perinatal M ortality 19 84.2 60.4 - 96.6 8 75.0 34.9 - 96.8 10 50.0 18.7 - 81.3 0.10
1983 - 1988 1989 - 1994 1995 - 2000
1983 - 1988 1989 - 1994 1995 - 2000
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Table 3 - P renatal diagnosis, pregnancy term ination, perinatal and early neonatal m ortality for selected (isolated) congenital heart anom alies - 
continued
iii) C oarctation of A orta
N %  95 %  C I* N %  95 %  C I* N %  95 %  C I* p

Prenatal D iagnosis 6 0 0 - 45.9 21 33.3 14.6 - 57.0 33 42.4 25.5 - 60.8 0.03
Pregnancy Term ination 6 0 0 - 45.9 21 0 0 - 16.1 34 0 0 - 10.3 -
First W eek M ortality 6 0 0 - 45.9 21 0 0 - 16.1 34 0 0 - 10.3 -
Perinatal M ortality 6 0 0 - 45.9 21 0 0 - 16.1 34 0 0 - 10.3 -
iv) Tetralogy of Fallot
N %  95 %  C I* N %  95 %  C I* N %  95 %  C I* p

Prenatal D iagnosis 10 20.0 2.5 - 55.6 16 37.5 15.2 - 64.6 33 69.7 51.3 - 84.4 0.005
Pregnancy Term ination 10 10.0 0.3 - 44.5 16 12.5 1.6 - 38.3 34 0 0 - 10.3 0.07
First W eek M ortality 9 0 0 - 33.6 13 0 0 - 24.7 33 0 0 - 10.6 -
Perinatal M ortality 9 0 0 - 33.6 14 7.1 0.2 - 33.9 34 2.9 0.1 - 0 .15 0.63
* 95%  binom ial exact confidence interval (97.5 %  one-sided confidence intervals for cases w ith zero events).

test of significance for cusum  linear annual trend
1983 - 1988 1989 - 1994 1995 - 2000
1983 - 1988 1989 - 1994 1995 - 2000
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Figure 2 – Cusum plot for analysis of time trends in early (< 1 week) neonatal mortality of congenital heart disease*, Paris Registry of 
Congenital Malformations, 1983 – 2000. The U-shaped curve suggests a monotonically decreasing trend in first-week mortality of 

























* Cases associated with chromosomal anomalies were excluded. 
 
